

## CollPlant licences out 3D bioprinting technology

25 October 2018 | News

**United Therapeutics will gain an exclusive licence to produce and use rhCollagen-based BioInk via CollPlant's wholly owned subsidiary Lung Biotechnology.**



Israeli regenerative medicine company CollPlant has signed a licence, development and commercialisation agreement with US-based biotechnology firm United Therapeutics regarding the 3D bioprinting of lung transplants.

The deal covers CollPlant's recombinant human collagen (rhCollagen) and BioInk technology, which is produced using raw materials from plants.

United Therapeutics will gain an exclusive licence to produce and use rhCollagen-based BioInk via CollPlant's wholly owned subsidiary Lung Biotechnology, which is involved in organ manufacturing and transplantation.

As per the terms of the agreement, the technology will be initially used for 3D bioprinting of solid-organ scaffolds for human lung transplants. United Therapeutics holds an option to further the licence for up to three additional organs.